|
- 2016
Fusion gene and splice variant analyses in liquid biopsies of lung cancer patientsAbstract: Lung cancer is the leading cause of cancer death worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of cases (1). The majority of the patients are diagnosed when the disease is locally advanced or metastatic and the overall 5-year survival rate is less than 20% (2). In the last years, driver alterations have been discovered in several oncogenes (3) such as KRAS, EGFR, ALK, MET, BRAF, PIK3CA, ROS1, HER2, RET, PTEN, NRG1, NTRK1, DDR2 or FGFR1. These alterations render the tumor sensitive to targeted agents that, in most cases, have significantly better clinical outcomes compared to standard chemotherapy (4-6)
|